MS pain is the uninvited guest you can't turn away, columnist Desiree Lama writes. Listening to your body is the key to ...

Bazedoxifene, a drug that alters the activity of the sex hormone estrogen, failed to promote myelin repair in women with MS, ...

Presentation raises questions about EBV timing. Dalia Rotstein, MD, of the University of Toronto, discussed the findings and their implications in an oral presentation at the Amer ...

In people with early MS, diet may correlate with biological aging and the development of disease-related disability, study ...

Tolebrutinib failed to lower disability progression risk in primary progressive MS in a Phase 3 trial, with data shown at ...

The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, ...

Scientists at the 2026 ACTRIMS forum meet to assess current approaches and explore new directions for MS research and care.

Researchers developed a mouse model of multiple sclerosis that captures the features of progression independent of relapse ...

After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...

Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...

A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.

BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...